Rodrigo Carlini Fernando

Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients

Mariana Bleker de Oliveira, Veruska L. Fook-Alves, Angela Isabel Pereira Eugênio et al. · Cancer Letters · 2017 · 37 citations

Medicine, Oncology, Pharmacology +14

Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism

Rodrigo Carlini Fernando, Diego R. Mazzotti, Hátylas Azevedo et al. · Scientific Reports · 2019 · 26 citations · Full text

Life Sciences, Cell Biology, Oncology +15

Multiple myeloma cell lines and primary tumors proteome: protein biosynthesis and Immune system as potential therapeutic targets

Rodrigo Carlini Fernando, Fabrício de Carvalho, Diego R. Mazzotti et al. · Genes & Cancer · 2015 · 22 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma

Angela Isabel Pereira Eugênio, Veruska L. Fook-Alves, Mariana Bleker de Oliveira et al. · Oncotarget · 2017 · 22 citations · Full text

Medicine, Hematology, Oncology +13

Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines

Rebecca S.S. Barbosa, Paola M. Dantonio, Taís Guimarães et al. · Biochemical and Biophysical Research Communications · 2019 · 21 citations

Medicine, Oncology, Pharmacology +17